| Characteristic . | All patients (n = 3984) . | ASAS Axial SpA (n = 2955) . | ASAS Peripheral SpA (n = 415) . |
|---|---|---|---|
| Male gender, n (%) | 2563 (65.0) | 1996 (67.5) | 225 (54.2) |
| Age, mean (s.d.), years | 43.6 (14.0) | 41.7 (13.2) | 51.1 (14.0) |
| Disease duration, mean (s.d.), years | 8.2 (9.3) | 8.6 (9.7) | 6.4 (7.6) |
| HLA-B27 positive/negative/missing, n (%) | 2217/844/923 (55.6/21.2/23.2) | 1980/546/428 (67.0/18.5/14.5) | 102/105/207 (24.6/25.3/49.9) |
| Current smoker, n (%) | 914 (22.9) | 717 (24.3) | 66 (15.9) |
| BMI (kg/m2), mean (s.d.) | 26.1 (5.7) | 25.9 (5.6) | 27.6 (6.4) |
| Currently employed, n (%) | 2325 (58.4) | 1766 (59.8) | 228 (54.9) |
| ASDAS-CRP, mean (s.d.) | 2.0 (1.1) | 2.0 (1.1) | 2.0 (1.0) |
| BASFI (0–10), mean (s.d.) | 3.0 (2.7) | 3.1 (2.7) | 2.8 (2.6) |
| EQ-5D (0–1), mean (s.d.) | 0.59 (0.34) | 0.58 (0.34) | 0.57 (0.34) |
| Global well-being (0–10), mean (s.d.) | 4.1 (2.6) | 4.1 (2.5) | 4.1 (2.6) |
| WPAI, impact on work productivity (0–10), mean (s.d.)a,b | 2.8 (2.6) | 2.8 (2.6) | 2.9 (3.0) |
| Impact on daily activities (0–10), mean (s.d.)a | 3.8 (2.9) | 3.8 (2.9) | 3.9 (2.9) |
| History of uveitis, n (%) | 769 (19.3) | 653 (22.1) | 44 (10.6) |
| History of psoriasis, n (%) | 841 (21.1) | 371 (12.6) | 240 (57.8) |
| History of IBD, n (%) | 208 (5.2) | 157 (5.3) | 17 (4.1) |
| mSCQ (0–39), mean (s.d.); median (range) | 1.9 (2.7); 1 (0–22) | 1.8 (2.6); 0 (0–21) | 2.5 (3.2); 2 (0–20) |
| mSCQ + EAMs (0–48), mean (s.d.); median (range) | 2.7 (3.2); 2 (0–29) | 2.4 (3.0); 1 (0–24) | 3.8 (3.8); 3 (0–29) |
| mSCQ + osteoporosis + fractures (0–45), mean (s.d.); median (range) | 2.1 (3.0); 1 (0–26) | 2.0 (2.8); 1 (0–24) | 2.7 (3.6); 2 (0–26) |
| mSCQ + EAMS + osteoporosis + fractures (0–54), mean (s.d.); median (range) | 2.9 (3.4); 2 (0–35) | 2.6 (3.2); 2 (0–27) | 4.1 (4.2); 3 (0–35) |
| RDCI (0–9), mean (s.d.); median (range) | 0.6 (1.0); 0 (0–8) | 0.5 (1.0); 0 (0–8) | 0.9 (1.2); 0 (0–8) |
| Characteristic . | All patients (n = 3984) . | ASAS Axial SpA (n = 2955) . | ASAS Peripheral SpA (n = 415) . |
|---|---|---|---|
| Male gender, n (%) | 2563 (65.0) | 1996 (67.5) | 225 (54.2) |
| Age, mean (s.d.), years | 43.6 (14.0) | 41.7 (13.2) | 51.1 (14.0) |
| Disease duration, mean (s.d.), years | 8.2 (9.3) | 8.6 (9.7) | 6.4 (7.6) |
| HLA-B27 positive/negative/missing, n (%) | 2217/844/923 (55.6/21.2/23.2) | 1980/546/428 (67.0/18.5/14.5) | 102/105/207 (24.6/25.3/49.9) |
| Current smoker, n (%) | 914 (22.9) | 717 (24.3) | 66 (15.9) |
| BMI (kg/m2), mean (s.d.) | 26.1 (5.7) | 25.9 (5.6) | 27.6 (6.4) |
| Currently employed, n (%) | 2325 (58.4) | 1766 (59.8) | 228 (54.9) |
| ASDAS-CRP, mean (s.d.) | 2.0 (1.1) | 2.0 (1.1) | 2.0 (1.0) |
| BASFI (0–10), mean (s.d.) | 3.0 (2.7) | 3.1 (2.7) | 2.8 (2.6) |
| EQ-5D (0–1), mean (s.d.) | 0.59 (0.34) | 0.58 (0.34) | 0.57 (0.34) |
| Global well-being (0–10), mean (s.d.) | 4.1 (2.6) | 4.1 (2.5) | 4.1 (2.6) |
| WPAI, impact on work productivity (0–10), mean (s.d.)a,b | 2.8 (2.6) | 2.8 (2.6) | 2.9 (3.0) |
| Impact on daily activities (0–10), mean (s.d.)a | 3.8 (2.9) | 3.8 (2.9) | 3.9 (2.9) |
| History of uveitis, n (%) | 769 (19.3) | 653 (22.1) | 44 (10.6) |
| History of psoriasis, n (%) | 841 (21.1) | 371 (12.6) | 240 (57.8) |
| History of IBD, n (%) | 208 (5.2) | 157 (5.3) | 17 (4.1) |
| mSCQ (0–39), mean (s.d.); median (range) | 1.9 (2.7); 1 (0–22) | 1.8 (2.6); 0 (0–21) | 2.5 (3.2); 2 (0–20) |
| mSCQ + EAMs (0–48), mean (s.d.); median (range) | 2.7 (3.2); 2 (0–29) | 2.4 (3.0); 1 (0–24) | 3.8 (3.8); 3 (0–29) |
| mSCQ + osteoporosis + fractures (0–45), mean (s.d.); median (range) | 2.1 (3.0); 1 (0–26) | 2.0 (2.8); 1 (0–24) | 2.7 (3.6); 2 (0–26) |
| mSCQ + EAMS + osteoporosis + fractures (0–54), mean (s.d.); median (range) | 2.9 (3.4); 2 (0–35) | 2.6 (3.2); 2 (0–27) | 4.1 (4.2); 3 (0–35) |
| RDCI (0–9), mean (s.d.); median (range) | 0.6 (1.0); 0 (0–8) | 0.5 (1.0); 0 (0–8) | 0.9 (1.2); 0 (0–8) |
Measured with the WPAI.
Only in patients currently employed (n = 2325). ASAS: Assessment SpondyloArthritis international Society; EAM: extra-articular manifestation; EQ-5D: Euroqol 5 D; mSCQ: modified self-administered comorbidity questionnaire; SpA: spondyloarthritis; RDCI: rheumatic disease comorbidity instrument; WPAI: work productivity and activity impairment.
| Characteristic . | All patients (n = 3984) . | ASAS Axial SpA (n = 2955) . | ASAS Peripheral SpA (n = 415) . |
|---|---|---|---|
| Male gender, n (%) | 2563 (65.0) | 1996 (67.5) | 225 (54.2) |
| Age, mean (s.d.), years | 43.6 (14.0) | 41.7 (13.2) | 51.1 (14.0) |
| Disease duration, mean (s.d.), years | 8.2 (9.3) | 8.6 (9.7) | 6.4 (7.6) |
| HLA-B27 positive/negative/missing, n (%) | 2217/844/923 (55.6/21.2/23.2) | 1980/546/428 (67.0/18.5/14.5) | 102/105/207 (24.6/25.3/49.9) |
| Current smoker, n (%) | 914 (22.9) | 717 (24.3) | 66 (15.9) |
| BMI (kg/m2), mean (s.d.) | 26.1 (5.7) | 25.9 (5.6) | 27.6 (6.4) |
| Currently employed, n (%) | 2325 (58.4) | 1766 (59.8) | 228 (54.9) |
| ASDAS-CRP, mean (s.d.) | 2.0 (1.1) | 2.0 (1.1) | 2.0 (1.0) |
| BASFI (0–10), mean (s.d.) | 3.0 (2.7) | 3.1 (2.7) | 2.8 (2.6) |
| EQ-5D (0–1), mean (s.d.) | 0.59 (0.34) | 0.58 (0.34) | 0.57 (0.34) |
| Global well-being (0–10), mean (s.d.) | 4.1 (2.6) | 4.1 (2.5) | 4.1 (2.6) |
| WPAI, impact on work productivity (0–10), mean (s.d.)a,b | 2.8 (2.6) | 2.8 (2.6) | 2.9 (3.0) |
| Impact on daily activities (0–10), mean (s.d.)a | 3.8 (2.9) | 3.8 (2.9) | 3.9 (2.9) |
| History of uveitis, n (%) | 769 (19.3) | 653 (22.1) | 44 (10.6) |
| History of psoriasis, n (%) | 841 (21.1) | 371 (12.6) | 240 (57.8) |
| History of IBD, n (%) | 208 (5.2) | 157 (5.3) | 17 (4.1) |
| mSCQ (0–39), mean (s.d.); median (range) | 1.9 (2.7); 1 (0–22) | 1.8 (2.6); 0 (0–21) | 2.5 (3.2); 2 (0–20) |
| mSCQ + EAMs (0–48), mean (s.d.); median (range) | 2.7 (3.2); 2 (0–29) | 2.4 (3.0); 1 (0–24) | 3.8 (3.8); 3 (0–29) |
| mSCQ + osteoporosis + fractures (0–45), mean (s.d.); median (range) | 2.1 (3.0); 1 (0–26) | 2.0 (2.8); 1 (0–24) | 2.7 (3.6); 2 (0–26) |
| mSCQ + EAMS + osteoporosis + fractures (0–54), mean (s.d.); median (range) | 2.9 (3.4); 2 (0–35) | 2.6 (3.2); 2 (0–27) | 4.1 (4.2); 3 (0–35) |
| RDCI (0–9), mean (s.d.); median (range) | 0.6 (1.0); 0 (0–8) | 0.5 (1.0); 0 (0–8) | 0.9 (1.2); 0 (0–8) |
| Characteristic . | All patients (n = 3984) . | ASAS Axial SpA (n = 2955) . | ASAS Peripheral SpA (n = 415) . |
|---|---|---|---|
| Male gender, n (%) | 2563 (65.0) | 1996 (67.5) | 225 (54.2) |
| Age, mean (s.d.), years | 43.6 (14.0) | 41.7 (13.2) | 51.1 (14.0) |
| Disease duration, mean (s.d.), years | 8.2 (9.3) | 8.6 (9.7) | 6.4 (7.6) |
| HLA-B27 positive/negative/missing, n (%) | 2217/844/923 (55.6/21.2/23.2) | 1980/546/428 (67.0/18.5/14.5) | 102/105/207 (24.6/25.3/49.9) |
| Current smoker, n (%) | 914 (22.9) | 717 (24.3) | 66 (15.9) |
| BMI (kg/m2), mean (s.d.) | 26.1 (5.7) | 25.9 (5.6) | 27.6 (6.4) |
| Currently employed, n (%) | 2325 (58.4) | 1766 (59.8) | 228 (54.9) |
| ASDAS-CRP, mean (s.d.) | 2.0 (1.1) | 2.0 (1.1) | 2.0 (1.0) |
| BASFI (0–10), mean (s.d.) | 3.0 (2.7) | 3.1 (2.7) | 2.8 (2.6) |
| EQ-5D (0–1), mean (s.d.) | 0.59 (0.34) | 0.58 (0.34) | 0.57 (0.34) |
| Global well-being (0–10), mean (s.d.) | 4.1 (2.6) | 4.1 (2.5) | 4.1 (2.6) |
| WPAI, impact on work productivity (0–10), mean (s.d.)a,b | 2.8 (2.6) | 2.8 (2.6) | 2.9 (3.0) |
| Impact on daily activities (0–10), mean (s.d.)a | 3.8 (2.9) | 3.8 (2.9) | 3.9 (2.9) |
| History of uveitis, n (%) | 769 (19.3) | 653 (22.1) | 44 (10.6) |
| History of psoriasis, n (%) | 841 (21.1) | 371 (12.6) | 240 (57.8) |
| History of IBD, n (%) | 208 (5.2) | 157 (5.3) | 17 (4.1) |
| mSCQ (0–39), mean (s.d.); median (range) | 1.9 (2.7); 1 (0–22) | 1.8 (2.6); 0 (0–21) | 2.5 (3.2); 2 (0–20) |
| mSCQ + EAMs (0–48), mean (s.d.); median (range) | 2.7 (3.2); 2 (0–29) | 2.4 (3.0); 1 (0–24) | 3.8 (3.8); 3 (0–29) |
| mSCQ + osteoporosis + fractures (0–45), mean (s.d.); median (range) | 2.1 (3.0); 1 (0–26) | 2.0 (2.8); 1 (0–24) | 2.7 (3.6); 2 (0–26) |
| mSCQ + EAMS + osteoporosis + fractures (0–54), mean (s.d.); median (range) | 2.9 (3.4); 2 (0–35) | 2.6 (3.2); 2 (0–27) | 4.1 (4.2); 3 (0–35) |
| RDCI (0–9), mean (s.d.); median (range) | 0.6 (1.0); 0 (0–8) | 0.5 (1.0); 0 (0–8) | 0.9 (1.2); 0 (0–8) |
Measured with the WPAI.
Only in patients currently employed (n = 2325). ASAS: Assessment SpondyloArthritis international Society; EAM: extra-articular manifestation; EQ-5D: Euroqol 5 D; mSCQ: modified self-administered comorbidity questionnaire; SpA: spondyloarthritis; RDCI: rheumatic disease comorbidity instrument; WPAI: work productivity and activity impairment.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
